NYU Langone Hospital Long Island

Clinical research site in Mineola, New York · Comprehensive Stroke Center at NYU Langone Hospital—Long Island, 259 1st St, Mineola, NY 11501 · (516) 663-0333 · Website

Part of NYU Langone

As of July 2026, 66 paid clinical trials are recruiting at NYU Langone Hospital Long Island in Mineola, New York. Active studies at this site cover conditions such as Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at NYU Langone Hospital Long Island (66)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

for Pancreatic Cancer

28 locations incl. Fort Smith

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07409272·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

28 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for End Stage Kidney Disease

147 locations incl. Decatur

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

66 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

32 locations incl. Birmingham

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

The PREDICT Registry:

for DCIS

30 locations incl. Scottsdale

Sponsor: PreludeDx

Sex: Female·Age: 30 - 85

Code: NCT03448926·Recruiting·Listed Feb 2018

Apply to this trial

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

for Extensive Stage-small Cell Lung Cancer

25 locations incl. Birmingham

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06362252·Phase 1, Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

for Aortic Stenosis, Calcific

50 locations incl. Huntsville

Sponsor: Edwards Lifesciences

Sex: All·Age: 65+

Code: NCT04889872·Recruiting·Listed May 2021

Apply to this trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for Non-Small Cell Lung Cancer

11 locations incl. New Haven

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05789082·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

for Myelodysplastic Syndromes

22 locations incl. Los Angeles

Sponsor: Taiho Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04256317·Phase 2, Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

for Pressure Ulcers Stage II

13 locations incl. San Diego

Sponsor: ULURU Inc.

Sex: All·Age: 18 - 85·Accepts healthy volunteers

Code: NCT05496296·Recruiting·Listed Aug 2022

Apply to this trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

for Non Small Cell Lung Cancer (Squamous or Non Squamous)

9 locations incl. Daphne

Sponsor: Eikon Therapeutics

Sex: All·Age: 18+

Code: NCT07365319·Phase 2, Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

for Ovarian Neoplasms

9 locations incl. Scottsdale

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06400472·Phase 1·Recruiting·Listed May 2024

Apply to this trial

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

for Endometrial Cancer

8 locations incl. Washington D.C.

Sponsor: BioNTech SE

Sex: Female·Age: 18+

Code: NCT06340568·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

387 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

525 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

261 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

224 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

430 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

227 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

316 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

382 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

206 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

221 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting·Listed Mar 2013

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

346 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

257 locations incl. Tucson

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

177 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

188 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

141 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

153 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

Showing the 40 most relevant of 66 recruiting trials at this site. Browse all with filters →

More research sites in Mineola

NYU Langone Hospital - Long Island (53 trials)
Perlmutter Cancer Center at NYU Langone Hospital - Long Island (12 trials)
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island (5 trials)
NYU Langone Health (4 trials)
NYU Langone Health - Long Island (3 trials)
NYU Langone Hospital-Long Island (2 trials)
NYU Langone Nephrology Associates-Mineola (2 trials)
New York University Langone Hospital - Long Island (2 trials)
Perlmutter Cancer Center at NYU Long Island (2 trials)
Winthrop University Hospital (2 trials)

Explore more

Paid clinical trials in Mineola, NY · New York clinical trials